From the Section of Nuclear Medicine, Department of Radiology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA.
Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville, TN.
Clin Nucl Med. 2019 Oct;44(10):789-791. doi: 10.1097/RLU.0000000000002792.
July 1, 2019, JAMA Internal Medicine released online an article authored by Kitahara et al entitled "Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism." The Altmetric Attention Score, a global indicator of interest from lay public and colleagues, skyrocketed to 223 by July 7, placing the article in the top 5% of all scored reports. The overall perception of death from cancer risk associated with I is inflated and not supported by evidence. As co-authors of this article, we offer previously unpublished data and analysis that (1) disputes clinical significance of the associated risk from I and (2) shows, again, that antithyroid drugs carry a statistically significant and a much more obvious cancer death risk.
2019 年 7 月 1 日，《美国医学会杂志-内科学》在线发表了由 Kitahara 等人撰写的题为“放射性碘治疗与甲状腺功能亢进患者癌症死亡率的关系”的文章。到 7 月 7 日，Altmetric 关注度（一个衡量公众和同行兴趣的全球指标）飙升至 223，使该文章跻身所有评分报告的前 5%。与 I 相关的癌症死亡风险的总体认知被夸大了，并且没有得到证据的支持。作为这篇文章的共同作者，我们提供了以前未发表的数据和分析，（1）质疑 I 相关风险的临床意义，（2）再次表明抗甲状腺药物具有统计学意义且更明显的癌症死亡风险。
